Tradewinds LLC. Takes $32,000 Position in Neuronetics, Inc. (NASDAQ:STIM)

Tradewinds LLC. bought a new position in shares of Neuronetics, Inc. (NASDAQ:STIM) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 20,000 shares of the company’s stock, valued at approximately $32,000.

Other large investors have also recently made changes to their positions in the company. David J Yvars Group grew its holdings in Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after acquiring an additional 14,825 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Neuronetics by 10,954.1% during the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock worth $88,000 after purchasing an additional 54,442 shares during the last quarter. Finally, HighTower Advisors LLC lifted its position in shares of Neuronetics by 55.5% during the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after purchasing an additional 87,816 shares during the last quarter. 53.59% of the stock is currently owned by hedge funds and other institutional investors.

Neuronetics Stock Performance

Shares of Neuronetics stock opened at $3.78 on Wednesday. The firm has a market capitalization of $114.72 million, a P/E ratio of -3.07 and a beta of 2.07. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. Neuronetics, Inc. has a 52 week low of $0.52 and a 52 week high of $5.92. The firm’s 50 day moving average is $4.08 and its two-hundred day moving average is $2.19.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group raised their price target on Neuronetics from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th.

Insider Activity at Neuronetics

In other Neuronetics news, CFO Stephen Furlong sold 17,307 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $4.11, for a total value of $71,131.77. Following the completion of the transaction, the chief financial officer now owns 454,420 shares in the company, valued at $1,867,666.20. This represents a 3.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP William Andrew Macan sold 12,175 shares of Neuronetics stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $46,630.25. Following the sale, the executive vice president now owns 388,647 shares in the company, valued at $1,488,518.01. This trade represents a 3.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 100,369 shares of company stock valued at $358,929 in the last ninety days. Insiders own 9.80% of the company’s stock.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.